3'-Selenobisalanine" No Further a Mystery
All enrolled individuals who gained no less than 1 dose of zosuquidar or placebo for the duration of induction were being monitored to the incidence of adverse situations (439 patients, 219 on zosuquidar and 210 on placebo). The commonest adverse occasions had been connected to the duration of extended and sizeable myelosuppression as is predicted